- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer treatment according to BRCA1 and BRCA2 mutations
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 9, Issue 9, Pages 520-528
Publisher
Springer Nature
Online
2012-07-24
DOI
10.1038/nrclinonc.2012.123
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.
- (2017) M. J. Birrer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.
- (2017) R. T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
- (2017) R. Rosell et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic/Familial High-Risk Assessment: Breast and Ovarian
- (2017) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Crizotinib and Testing for ALK
- (2017) Alice T. Shaw et al. Journal of the National Comprehensive Cancer Network
- Advances in using PARP inhibitors to treat cancer
- (2012) Shivaani Kummar et al. BMC Medicine
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
- (2012) Harkanwal Halait et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Dissecting the Heterogeneity of Triple-Negative Breast Cancer
- (2012) Otto Metzger-Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA patent dispute may head to US Supreme Court
- (2012) Sharmila Devi LANCET
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression
- (2012) Thomas Ernst et al. SEMINARS IN ONCOLOGY
- Hereditary breast cancer: clinical features and risk reduction strategies
- (2011) A. Paradiso et al. ANNALS OF ONCOLOGY
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
- (2011) Sarah F. Adams et al. GYNECOLOGIC ONCOLOGY
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
- (2011) Shiyu Zhang et al. GYNECOLOGIC ONCOLOGY
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons FromBRCA1/2-Associated Breast Cancer
- (2011) Susan M. Domchek et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Systemic Therapy for Breast Cancer inBRCAMutation Carriers and Noncarriers: A Single-Institution Experience
- (2011) Banu Arun et al. JOURNAL OF CLINICAL ONCOLOGY
- Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer
- (2011) Veronica Dussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
- (2010) P. J. O'Donovan et al. CARCINOGENESIS
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers
- (2010) Robert Cook-Deegan et al. GENETICS IN MEDICINE
- Breast Cancer Predisposition Syndromes
- (2010) Deborah Hemel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
- (2010) Susan M. Domchek JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Pitfalls of Retrospective and Nonrandomized Comparison of Treatment Modalities
- (2010) Ajay P. Sandhu JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
- (2010) Christiane Kuhl et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- Familial Syndromes Associated with Thyroid Cancer in the Era of Personalized Medicine
- (2010) Melanie L. Richards THYROID
- An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
- (2009) Rachael Natrajan et al. BREAST CANCER RESEARCH AND TREATMENT
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
- (2009) T John et al. ONCOGENE
- BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research
- (2008) Susan L. Neuhausen et al. BREAST CANCER RESEARCH AND TREATMENT
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Can genetic testing guide treatment in breast cancer?
- (2008) Andrew Tutt et al. EUROPEAN JOURNAL OF CANCER
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now